

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 September 2003 (04.09.2003)

PCT

(10) International Publication Number  
**WO 03/072033 A2**



- (51) International Patent Classification<sup>7</sup>: **A61K**
- (21) International Application Number: PCT/US03/05225
- (22) International Filing Date: 19 February 2003 (19.02.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
10/081,989 21 February 2002 (21.02.2002) US
- (71) Applicant (for all designated States except US): **TRIAD THERAPEUTICS, INC.** [US/US]; 9381 Judicial Drive, San Diego, CA 92121 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **YU, Lin** [CN/US];

11597 Tree Hollow Lane, San Diego, CA 92128 (US). **DONG, Qing** [CN/US]; 11087 Morning Creek Drive South, San Diego, CA 92128-4047 (US). **PIERRE, Fabrice** [FR/US]; 8544 Villa La Jolla Drive, Apt. 199, La Jolla, CA 92037-8314 (US). **CHANG, Edcon** [US/US]; 10616 Brookhollow Court, San Diego, CA 92126 (US). **LANG, Hengyuan** [CN/US]; 10676 Brookhollow Court, San Diego, CA 92126 (US). **QIN, Yong** [CN/US]; 13875 Wayland Grove Court, Poway, CA 92064 (US). **FANG, Yunfeng** [CN/US]; 12029 World Trade Drive, Unit 4, San Diego, CA 92128 (US). **HANSEN, Mark, R.** [US/US]; 5275 Toscana Way #121, San Diego, CA 92122 (US). **PELLECCHIA, Maurizio** [IT/US]; 4386 Campus Avenue, San Diego, CA 92103 (US).

(74) Agents: **CADENA, Deborah, L.** et al.; McDermott, Will & Emery, 4370 La Jolla Village Drive, 7th Floor, San Diego, CA 92122 (US).

[Continued on next page]

(54) Title: COMMON LIGAND MIMICS: THIAZOLIDINEDIONES AND RHODANINES



(57) Abstract: The present invention provides common ligand mimics that act as common ligands for a receptor family. The present invention also provides bi-ligands containing these common ligand mimics. Bi-ligands of the invention provide enhanced affinity and/or selectivity of ligand binding to a receptor or receptor family through the synergistic action of the common ligand mimic and specificity ligand which compose the bi-ligand. The present invention also provides combinatorial libraries containing the common ligand mimics and bi-ligands of the invention. Further, the present invention provides methods for manufacturing the common ligand mimics and bi-ligands of the invention and methods for assaying the combinatorial libraries of the invention.



**(81) Designated States (national):** AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

**(84) Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**COMMON LIGAND MIMICS: THIAZOLIDINEDIONES AND RHODANINES****BACKGROUND OF THE INVENTION****FIELD OF THE INVENTION**

5 The present invention relates generally to  
receptor/ligand interactions and to combinatorial  
libraries of ligand compounds. The present invention  
also relates to the manufacture of thiazolidinediones and  
rhodanines and combinatorial libraries containing such  
compounds.

10

**BACKGROUND INFORMATION**

Two general approaches have traditionally been  
used for drug discovery: screening for lead compounds and  
structure-based drug design. Both of these approaches  
are laborious and time-consuming and often produce  
15 compounds that lack the desired affinity or specificity.

Screening for lead compounds involves  
generating a pool of candidate compounds, often using  
combinatorial chemistry approaches in which compounds are  
synthesized by combining chemical groups to generate a  
20 large number of diverse candidate compounds that bind to  
the target or that inhibit binding to the target. The  
candidate compounds are screened with a drug target of  
interest to identify lead compounds that bind to the  
target or inhibit binding to the target. However, the

screening process to identify a lead compound can be laborious and time consuming.

Structure-based drug design is an alternative approach to identifying drug candidates. Structure-based  
5 drug design uses three-dimensional structural data of the drug target as a template to model compounds that bind to the drug target and alter its activity. The compounds identified as potential drug candidates using structural modeling are used as lead compounds for the development  
10 of drug candidates that exhibit a desired activity toward the drug target.

Identifying compounds using structure-based drug design can be advantageous when compared to the screening approach in that modifications to the compound  
15 can often be predicted by modeling studies. However, obtaining structures of relevant drug targets and of drug targets complexed with test compounds is extremely time-consuming and laborious, often taking years to accomplish. The long time period required to obtain  
20 structural information useful for developing drug candidates is particularly limiting with regard to the growing number of newly discovered genes, which are potential drug targets, identified in genomics studies.

Despite the time-consuming and laborious nature  
25 of these approaches to drug discovery, both screening for lead compounds and structure-based drug design have led to the identification of a number of useful drugs, such as receptor agonists and antagonists. However, many of the drugs identified by these approaches have unwanted

toxicity or side effects. Therefore, there is a need in the art for drugs that have high specificity and reduced toxicity. For example, in addition to binding to the drug target in a pathogenic organism or cancer cell, in some cases the drug also binds to an analogous protein in the patient being treated with the drug, which can result in toxic or unwanted side effects. Therefore, drugs that have high affinity and specificity for a target are particularly useful because administration of a more specific drug at lower dosages will minimize toxicity and side effects.

In addition to drug toxicity and side effects, a number of drugs that were previously highly effective for treating certain diseases have become less effective during prolonged clinical use due to the development of resistance. Drug resistance has become increasingly problematic, particularly with regard to administration of antibiotics. A number of pathogenic organisms have become resistant to several drugs due to prolonged clinical use and, in some cases, have become almost totally resistant to currently available drugs. Furthermore, certain types of cancer develop resistance to cancer therapeutic agents. Therefore, drugs that are refractile to the development of resistance would be particularly desirable for treatment of a variety of diseases.

One approach to developing such drugs is to find compounds that bind to a target protein such as a receptor or enzyme. When such a target protein has two adjacent binding sites, it is especially useful to find

"bi-ligand" drugs that can bind at both sites simultaneously. However, the rapid identification of bi-ligand drugs having the optimum combination of affinity and specificity has been difficult. Bi-ligand drug candidates have been identified using rational drug design, but previous methods are time-consuming and require a precise knowledge of structural features of the receptor. Recent advances in nuclear magnetic spectroscopy (NMR) have allowed the determination of the three-dimensional interactions between a ligand and a receptor in a few instances. However, these efforts have been limited by the size of the receptor and can take years to map and analyze the complete structure of the complexes of receptor and ligand.

Thus, there exists a need for compounds that bind to multiple members of a receptor family. There is also a need for receptor bi-ligands containing such compounds coupled to ligands having a high specificity for the receptor.


There is a further need in the art for methods of preparing such compounds and bi-ligands. There is also a need in the art for methods of preparing combinatorial libraries of the bi-ligands and methods of screening these libraries to find bi-ligands that interact with a drug target with improved affinity and/or specificity. The present invention satisfies these needs and provides related advantages as well.

SUMMARY OF THE INVENTION

The present invention provides compounds that function as mimics to a natural common ligand for a receptor family. These compounds interact with a conserved binding site on multiple receptors within the receptor family.

In one aspect, the present invention provides compounds that are common ligand mimics for NAD. NAD is a natural common ligand for many oxidoreductases. Thus, compounds of the invention that are common ligand mimics for NAD interact selectively with conserved sites on oxidoreductases.

In one embodiment, the present invention provides compounds of Formula I,




15

20

wherein  $R_1$  to  $R_8$  each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOAlkyl, CONR<sub>10</sub>R<sub>11</sub>, C(O)R<sub>12</sub>, OH, OAlkyl, OAc, SH, SR<sub>12</sub>, SO<sub>3</sub>H, S(O)R<sub>12</sub>, SO<sub>2</sub>NR<sub>10</sub>R<sub>11</sub>, S(O)<sub>2</sub>R<sub>12</sub>, NH<sub>2</sub>, NHR<sub>12</sub>, NR<sub>10</sub>R<sub>11</sub>, NHCOR<sub>12</sub>, NR<sub>10</sub>COR<sub>12</sub>, N<sub>3</sub>, NO<sub>2</sub>, PH<sub>3</sub>, PH<sub>2</sub>R<sub>12</sub>, H<sub>2</sub>PO<sub>4</sub>, H<sub>2</sub>PO<sub>3</sub>, H<sub>2</sub>PO<sub>2</sub>, HPO<sub>4</sub>R<sub>12</sub>, PO<sub>2</sub>R<sub>11</sub>R<sub>12</sub>, CN, or X.  $R_9$  is an oxygen, sulfur, or nitrogen atom, where the nitrogen atom can be substituted, e.g. NR<sub>12</sub>; and

$R_{10}$ ,  $R_{11}$ , and  $R_{12}$  each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or  $R_{10}$  and  $R_{11}$  together with the nitrogen to which they are attached can be joined to form a heterocyclic ring.


5 In another embodiment, the invention provides thiazolidinedione compounds of Formula II,



10 wherein  $R_1$  to  $R_8$  each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOAlkyl, CONR<sub>10</sub>R<sub>11</sub>, C(O)R<sub>12</sub>, OH, OAlkyl, OAc, SH, SR<sub>12</sub>, SO<sub>3</sub>H, S(O)R<sub>12</sub>, SO<sub>2</sub>NR<sub>10</sub>R<sub>11</sub>, S(O)<sub>2</sub>R<sub>12</sub>, NH<sub>2</sub>, NHR<sub>12</sub>, NR<sub>10</sub>R<sub>11</sub>, NHCOR<sub>12</sub>, NR<sub>10</sub>COR<sub>12</sub>, N<sub>3</sub>, NO<sub>2</sub>, PH<sub>3</sub>, PH<sub>2</sub>R<sub>12</sub>, H<sub>2</sub>PO<sub>4</sub>, H<sub>2</sub>PO<sub>3</sub>, H<sub>2</sub>PO<sub>2</sub>, HPO<sub>4</sub>R<sub>12</sub>, PO<sub>2</sub>R<sub>11</sub>R<sub>12</sub>,  
 15 CN, or X.  $R_{10}$ ,  $R_{11}$ , and  $R_{12}$  each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or  $R_{10}$  and  $R_{11}$  together with the nitrogen to which they are attached can be joined to form a heterocyclic ring.

20 In still another embodiment, the invention provides rhodanine compounds of Formula III,





5 wherein  $R_1$  to  $R_8$  each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOAlkyl, CONR<sub>10</sub>R<sub>11</sub>, OH, OAlkyl, OAc, SH, SR<sub>12</sub>, SO<sub>3</sub>H, S(O)R<sub>12</sub>, SO<sub>2</sub>NR<sub>10</sub>R<sub>11</sub>, S(O)<sub>2</sub>R<sub>12</sub>, NH<sub>2</sub>, NHR<sub>12</sub>, NR<sub>10</sub>R<sub>11</sub>, NHCOR<sub>12</sub>, NR<sub>10</sub>COR<sub>12</sub>, N<sub>3</sub>, NO<sub>2</sub>, PH<sub>3</sub>, PH<sub>2</sub>R<sub>12</sub>, H<sub>2</sub>PO<sub>4</sub>, H<sub>2</sub>PO<sub>3</sub>, H<sub>2</sub>PO<sub>2</sub>, HPO<sub>4</sub>R<sub>12</sub>, PO<sub>2</sub>R<sub>11</sub>R<sub>12</sub>, CN, or X.  $R_{10}$ ,  $R_{11}$ ,  
10 and  $R_{12}$  each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or  $R_{10}$  and  $R_{11}$  together with the nitrogen to which they are attached can be joined to form a heterocyclic ring.

In a second aspect, the present invention  
15 provides methods for preparing compounds of Formula I. These methods generally comprise two steps. In the first step of each method, a furaldehyde intermediate is formed. In the second step, the furaldehyde intermediate is reacted either with 2,4-thiazolidinedione to form a  
20 compound of Formula II or with rhodanine to form a compound of Formula III.

In a third aspect, the present invention  
provides bi-ligands containing a common ligand mimic and a specificity ligand which interact with distinct sites  
25 on a receptor. In one embodiment, the present invention provides bi-ligands that are the reaction products of

compounds of Formula I with specificity ligands. In another embodiment, the invention provides bi-ligands containing the reaction products of compounds of Formula II with specificity ligands. In yet another embodiment, the invention provides bi-ligands that are reaction products of compounds of Formula III and specificity ligands. In yet another aspect, the invention provides methods for preparing bi-ligands that are reaction products of the common ligand mimics of general Formulas I, II, and III and a pyridine dicarboxylate specificity ligand.

The present invention further provides combinatorial libraries containing one or more common ligand variants of the compounds of the invention. In one embodiment, the combinatorial libraries of the invention contain one or more common ligand variants of the compounds of Formula I. In other embodiments, the combinatorial libraries of the invention contain one or more common ligand variants of the compounds of Formula II or Formula III.

The present invention also provides combinatorial libraries comprised of one or more bi-ligands that are reaction products of common ligand mimics and specificity ligands. In one embodiment, such combinatorial libraries contain one or more bi-ligands that are the reaction product of compounds of Formula I and specificity ligands. In another embodiment, such combinatorial libraries contain one or more bi-ligands that are the reaction product of compounds of Formula II and specificity ligands. In still another embodiment,

such combinatorial libraries contain one or more bi-ligands that are the reaction product of compounds of Formula III and specificity ligands.

5 The present invention also provides methods for producing and screening combinatorial libraries of bi-ligands for binding to a receptor and families of such receptors.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 shows Scheme 1 for the synthesis of thiazolidinedione compounds of Formula II where  $R_1$  to  $R_8$  each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOAlkyl, CONR<sub>10</sub>R<sub>11</sub>, C(O)R<sub>12</sub>, OH, OAlkyl, OAc, SH, SR<sub>12</sub>, SO<sub>3</sub>H, S(O)R<sub>12</sub>, SO<sub>2</sub>NR<sub>10</sub>R<sub>11</sub>, S(O)<sub>2</sub>R<sub>12</sub>, NH<sub>2</sub>, NHR<sub>12</sub>, NR<sub>10</sub>R<sub>11</sub>, NHCOR<sub>12</sub>, NR<sub>10</sub>COR<sub>12</sub>, N<sub>3</sub>, NO<sub>2</sub>, PH<sub>3</sub>, PH<sub>2</sub>R<sub>12</sub>, H<sub>2</sub>PO<sub>4</sub>, H<sub>2</sub>PO<sub>3</sub>, H<sub>2</sub>PO<sub>2</sub>, HPO<sub>4</sub>R<sub>12</sub>, PO<sub>2</sub>R<sub>11</sub>R<sub>12</sub>, CN, or X.  $R_{10}$ ,  $R_{11}$ , and  $R_{12}$  each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or  $R_{10}$  and  $R_{11}$  together with the nitrogen to which they are attached can be joined to form a heterocyclic ring. The reaction steps are as follows: (a) an aminobenzoic acid and 2-furaldehyde are reacted in the presence of HNO<sub>2</sub> and CuCl<sub>2</sub>/CuCl to form a furaldehyde intermediate; (b) the furaldehyde intermediate is reacted with 2,4-thiazolidinedione, while heating, to form the corresponding thiazolidinedione.

25 Figure 2 shows Scheme 1 for the synthesis of rhodanine compounds of Formula III where  $R_1$  to  $R_8$  each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOAlkyl, CONR<sub>10</sub>R<sub>11</sub>, C(O)R<sub>12</sub>, OH,

OAlkyl, OAc, SH, SR<sub>12</sub>, SO<sub>3</sub>H, S(O)R<sub>12</sub>, SO<sub>2</sub>NR<sub>10</sub>R<sub>11</sub>, S(O)<sub>2</sub>R<sub>12</sub>, NH<sub>2</sub>, NHR<sub>12</sub>, NR<sub>10</sub>R<sub>11</sub>, NHCOR<sub>12</sub>, NR<sub>10</sub>COR<sub>12</sub>, N<sub>3</sub>, NO<sub>2</sub>, PH<sub>3</sub>, PH<sub>2</sub>R<sub>12</sub>, H<sub>2</sub>PO<sub>4</sub>, H<sub>2</sub>PO<sub>3</sub>, H<sub>2</sub>PO<sub>2</sub>, HPO<sub>4</sub>R<sub>12</sub>, PO<sub>2</sub>R<sub>11</sub>R<sub>12</sub>, CN, or X. R<sub>10</sub>, R<sub>11</sub>, and R<sub>12</sub> each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or R<sub>10</sub> and R<sub>11</sub> together with the nitrogen to which they are attached can be joined to form a heterocyclic ring.. The reaction steps are as follows: (a) an aminobenzoic acid and 2-furaldehyde are reacted in the presence of HNO<sub>2</sub> and CuCl<sub>2</sub>/CuCl to form a furaldehyde intermediate; (b) the furaldehyde intermediate is reacted with rhodanine, while heating, to form the corresponding rhodanine compound.

Figure 3 shows Scheme 2 for the synthesis of thiazolidinedione compounds of Formula II where R<sub>1</sub> to R<sub>8</sub> each independently are H, alkyl, alkenyl, alkynyl, aryl, heterocycle, COOH, COOAlkyl, CONR<sub>10</sub>R<sub>11</sub>, C(O)R<sub>12</sub>, OH, OAlkyl, OAc, SH, SR<sub>12</sub>, SO<sub>3</sub>H, S(O)R<sub>12</sub>, SO<sub>2</sub>NR<sub>10</sub>R<sub>11</sub>, S(O)<sub>2</sub>R<sub>12</sub>, NH<sub>2</sub>, NHR<sub>12</sub>, NR<sub>10</sub>R<sub>11</sub>, NHCOR<sub>12</sub>, NR<sub>10</sub>COR<sub>12</sub>, N<sub>3</sub>, NO<sub>2</sub>, PH<sub>3</sub>, PH<sub>2</sub>R<sub>12</sub>, H<sub>2</sub>PO<sub>4</sub>, H<sub>2</sub>PO<sub>3</sub>, H<sub>2</sub>PO<sub>2</sub>, HPO<sub>4</sub>R<sub>12</sub>, PO<sub>2</sub>R<sub>11</sub>R<sub>12</sub>, CN, or X. R<sub>10</sub>, R<sub>11</sub>, and R<sub>12</sub> each independently are hydrogen, alkyl, alkenyl, alkynyl, aryl, or heterocycle, or R<sub>10</sub> and R<sub>11</sub> together with the nitrogen to which they are attached can be joined to form a heterocyclic ring. The reaction steps are as follows: (a) a halobenzoate and 5-trimethylstannanyl-furan-2-carbaldehyde are reacted in the presence of Pd(PPh<sub>3</sub>)<sub>4</sub> to form a furaldehyde intermediate; (b) the furaldehyde intermediate is reacted with 2,4-thiazolidinedione while heating, to form the corresponding thiazolidinedione.